Table 3.

Risk of any and increasingly advanced prostate cancer associated with CASP8 D302H in the PLCO Cancer Screening Trial

PLCO Population	MAF Controls	MAF Cases	Per Allele OR* (95% CI) [H vs D]	Heterozygous OR* (95% CI) [DH vs DD]	Homozygous OR* (95% CI) [HH vs DD]	Dominant OR* (95% CI) [DH, HH vs DD]	Ptrend
Entire Cohort	0.133	0.126	0.94 (0.79–1.11)	0.91 (0.75–1.11)	1.03 (0.55–1.95)	0.92 (0.76–1.11)	0.46
Gleason ≤ 6 And Stage cT1–2	0.133	0.131	0.98 (0.79–1.23)	0.95 (0.74–1.23)	1.17 (0.52–2.60)	0.98 (0.75–1.24)	0.88
Gleason 7–10 OR Stage cT3–4	0.133	0.123	0.91 (0.74–1.11)	0.89 (0.71–1.11)	0.95 (0.45–2.01)	0.89 (0.71–1.11)	0.34
Gleason 8–10 OR Stage cT3–4	0.133	0.116	0.85 (0.65–1.12)	0.88 (0.65–1.19)	0.57 (0.11–1.95) †	0.86 (0.64–1.15)	0.25
Gleason 7–10 AND Stage cT3–4	0.133	0.101	0.73 (0.50–1.07)	0.76 (0.50–1.15)	0.35 (0.008–2.25) †	0.73 (0.49–1.10)	0.11
Gleason 8–10 AND Stage cT3–4	0.133	0.075	0.52 (0.24–1.14)	0.56 (0.25–1.27)	-	0.52 (0.23–1.18)	0.10

^*Odds ratios are adjusted for age

^†Exact confidence interval calculated